QRG Capital Management Inc. Decreases Stock Holdings in Novo Nordisk A/S $NVO

QRG Capital Management Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 44.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 129,331 shares of the company’s stock after selling 103,385 shares during the period. QRG Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $7,177,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC grew its holdings in Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 1.5% during the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after acquiring an additional 187,789 shares during the last quarter. Sustainable Growth Advisers LP grew its stake in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after acquiring an additional 649,390 shares during the last quarter. State Street Corp raised its position in shares of Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after purchasing an additional 47,430 shares during the last quarter. Finally, DAVENPORT & Co LLC boosted its stake in Novo Nordisk A/S by 54.8% in the 3rd quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after purchasing an additional 935,468 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NVO shares. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Wednesday. The Goldman Sachs Group reduced their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, November 28th. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Finally, Jefferies Financial Group began coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $56.21.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.
• Positive Sentiment: Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.
• Positive Sentiment: U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.
• Neutral Sentiment: Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.
• Neutral Sentiment: High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.
• Negative Sentiment: Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.
• Negative Sentiment: Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $62.32 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The business’s 50 day moving average is $50.85 and its two-hundred day moving average is $54.97. The company has a market capitalization of $278.26 billion, a P/E ratio of 18.12 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.